Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Plant-derived extracellular vesicles in skin and bone tissue engineering: current status, challenges, and future perspectives

Lu C., Li D., Gao W., Sun X., Zhang Y., Yu Y.

Narrative Review on Immune Modulation, published in Front Bioeng Biotechnol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Bioeng Biotechnol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41938063
PMCID
PMC13044024
DOI
10.3389/fbioe.2026.1764724

Abstract (original English)

Plant-derived extracellular vesicles (PDEVs) are bioactive nanoscale vesicles secreted by plant cells, which have recently gained attention as promising therapeutic agents in tissue engineering owing to their low immunogenicity, inherent biological activities, and potential as drug delivery vehicles. This review comprehensively outlines the general properties, application-specific characteristics, and isolation techniques of PDEVs, with a particular emphasis on their roles in facilitating cell proliferation, differentiation, and immunomodulation to promote tissue regeneration. We further discuss the therapeutic efficacy of PDEVs derived from various plant sources across different tissue engineering contexts, as well as the application of engineered PDEVs in tailored regenerative strategies. In comparison to mammalian extracellular vesicles, PDEVs present distinct advantages, including minimized ethical concerns and reduced risks of immune rejection. Nevertheless, challenges remain for their clinical translation, such as the lack of standardized isolation protocols and inadequate assessment of long-term in vivo safety. This article synthesizes current understanding of PDEVs, underscores their multifunctional potential, and offers perspectives on engineering approaches aimed at enhancing their therapeutic performance. With continued development, PDEVs may emerge as innovative too

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research